{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:45Z","timestamp":1793060025593,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.msard.2019.101504","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T23:24:27Z","timestamp":1572996267000},"page":"101504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-2500","authenticated-orcid":false,"given":"M.","family":"di Ioia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Di Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pietrolongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Onofrj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2019.101504_bib0001","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","article-title":"Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations","volume":"265","author":"Devonshire","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101504_bib0002","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, care-ms I, and care-ms II studies and the CAMMS03409 extension study","author":"Wray","year":"2018","journal-title":"Mult. Scler."},{"issue":"9856","key":"10.1016\/j.msard.2019.101504_bib0003","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2019.101504_bib0004","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2019.101504_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2019.101504_bib0006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.expneurol.2014.04.018","article-title":"Mode of action and clinical studies with alemtuzumab","volume":"262","author":"Jones","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.msard.2019.101504_bib0007","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1352458517743093","article-title":"Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria duringalemtuzumab treatment for multiple sclerosis","volume":"6","author":"di Ioia","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101504_bib0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.msard.2018.11.029","article-title":"Acquired haemophilia a as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report","volume":"27","author":"Pisa","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101504_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226588","article-title":"Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis","author":"Madeley","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2019.101504_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223016","article-title":"Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep."},{"issue":"50","key":"10.1016\/j.msard.2019.101504_bib0011","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"8","key":"10.1016\/j.msard.2019.101504_bib0012","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2019.101504_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2019.101504_bib0014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the Mcdonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.101504_bib0015","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/TCRM.S143509","article-title":"Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the alemtuzumab clinical development program","volume":"13","author":"Havrdova","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.msard.2019.101504_bib0016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2019.101504_bib0017","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ana.20740","article-title":"Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients","volume":"59","author":"R\u00edo","year":"2006","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2019.101504_bib0018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1352458511399611","article-title":"Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis","volume":"17","author":"Phillips","year":"2011","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2019.101504_bib0019","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumabtreatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J. Neurol."},{"issue":"19","key":"10.1016\/j.msard.2019.101504_bib0020","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","article-title":"Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients","volume":"87","author":"Giovannoni","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2019.101504_bib0021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","article-title":"Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy","volume":"16","author":"Haghikia","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2019.101504_bib0022","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40120-016-0058-0","article-title":"High-Risk PML patients switching from natalizumab to alemtuzumab: an observational study","volume":"6","author":"Malucchi","year":"2017","journal-title":"Neurol. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819304936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819304936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:24Z","timestamp":1761900564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819304936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":22,"alternative-id":["S2211034819304936"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101504","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101504"}}